Home › Funds › PAULSON & CO. INC. › MDGL

PAULSON & CO. INC. position in MDGL

MADRIGAL PHARMACEUTICALS INC · Health Care

PAULSON & CO. INC. reported holding 1,340,020 shares of MDGL (MADRIGAL PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$719.5M, representing 27.94% of its reported portfolio and ranking #1 among its reported holdings. PAULSON & CO. INC. has disclosed MDGL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.34M sh
Reported value held$719.52M
Portfolio Weight27.94%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How PAULSON & CO. INC.'s MDGL position evolved

PAULSON & CO. INC. first disclosed a stake in MDGL in Q3 2023 at 500,000 shares (US$73.0M). The position peaked in Q4 2025 at 1,707,522 shares, worth US$994.4M. Across 12 filings, PAULSON & CO. INC. increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 1,340,020 shares valued at US$719.5M — a reduction of -52,168 shares quarter over quarter.. Notable position changes include a 121% increase in Q4 2023 (shares rose 15% over the following quarter), a 61% increase in Q1 2024 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 500.00K $73.02M New
Q4 2023 1.11M $255.85M Add
Q1 2024 1.77M $474.00M Add
Q2 2024 1.85M $518.30M Add
Q3 2024 2.04M $392.61M Add
Q4 2024 2.04M $630.10M Hold
Q1 2025 2.10M $695.43M Add
Q2 2025 2.09M $632.37M Hold
Q3 2025 1.91M $874.90M Reduce
Q4 2025 1.71M $994.36M Reduce
Q1 2026 1.39M $728.77M Reduce
Q2 2026 1.34M $719.52M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MDGL and 13F data

MDGL (MADRIGAL PHARMACEUTICALS INC) is a Health Care company. 47 other funds we track also report a position in MDGL — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.15B), RTW INVESTMENTS, LP (US$1.07B), Janus Henderson Group (US$1.05B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MDGL

All MDGL fund holders →

FAQ

How long has PAULSON & CO. INC. held MDGL?

PAULSON & CO. INC. has disclosed MDGL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is PAULSON & CO. INC.'s current position in MDGL?

As of Q2 2026, PAULSON & CO. INC. holds 1.34M shares of MDGL (MADRIGAL PHARMACEUTICALS INC), valued at $719.52M, representing 27.94% of its reported portfolio and ranking #1.

Has PAULSON & CO. INC. been buying or selling MDGL?

In the latest 13F filing (Q2 2026), PAULSON & CO. INC. reduced its position in MDGL. The position peaked in Q4 2025 at 1.71M shares.

Which other funds hold MDGL?

Other major institutional holders of MDGL include BAKER BROS. ADVISORS LP, RTW INVESTMENTS, LP, Janus Henderson Group, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.